Maxim downgraded BrainStorm (BCLI) to Hold from Buy.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCLI:
- Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice
- BrainStorm announces Nasdaq delisting and transition to OTCQB
- Brainstorm Cell Therapeutics Approves Stock Plan Amendments
- BrainStorm files to sell 2.76M shares of common stock for holders
- Promising Survival Data and Regulatory Progress Bolster Buy Rating for Brainstorm Cell Therapeutics